Durvalumab in cancer medicine: a comprehensive review-Reference-Cited by-同舟云学术

Durvalumab in cancer medicine: a comprehensive review

Published:2019-07-05 Issue:9 Volume:19 Page:927-935
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Alvarez-Argote Juliana¹,Dasanu Constantin A.²³

Affiliation:

1. Department of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

2. Department of Hematology-Oncology, Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA, USA

3. Department of Hematology-Oncology, University of California San Diego Health System, San Diego, CA, USA

Funder

not funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1635115

Reference38 articles.

1. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

2. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody

3. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

4. U.S. Food and Drug Administration. Highlights of prescribing information. Imfinzi™ (durvalumab) injection, for intravenous use. 2017 [cited 2018]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf

5. U.S. Food and Drug Administration. FDA Summary of Safety and Effectiveness Data. (SSED). 2017 In vitro diagnostic immunohistochemistry (IHC) for detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) human tissue sections. [cited 2018 Nov 23] Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160046B.pdf

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives;Life;2024-08-25

2. Acquired generalized anhidrosis following durvalumab treatment in a patient with advanced non‐small cell lung cancer;The Journal of Dermatology;2024-07-23

3. Regulatory mechanisms of PD-1/PD-L1 in cancers;Molecular Cancer;2024-05-18

4. How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans;EJNMMI Physics;2024-02-07

5. Better safe than sorry: dual targeting antibodies for cancer immunotherapy;Biological Chemistry;2024-02-01